Johns Hopkins University Psilocybin & Cancer

44 cancer patients will receive psilocybin treatment similar to that in Dr. Grob's study, except that it includes early-stage cancer patients and a different research design that involves two psilocybin sessions and higher doses of psilocybin. This study specifically focuses on spiritual experience facilitated by psilocybin as a healing factor in patients who are psychologically distressed by their cancer diagnosis. Patients with and without disease progression are eligible. Outcome measures include measures of mystical/spiritual experience, quality of life, anxiety, depressed mood, attitude about death, use of pain medication, and blood markers of stress and immune function. Subject recruiting is ongoing, and potential subjects can be referred to the study coordinator, Mary Cosimano at (410) 550-5990, or by email to: Roland Griffiths.